• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

6-β-碘代青霉烷酸抑制 A 类β-内酰胺酶和青霉素结合蛋白的结构基础。

Structural basis of the inhibition of class A beta-lactamases and penicillin-binding proteins by 6-beta-iodopenicillanate.

机构信息

Centre d'Ingénierie des Protéines and Centre de Recherches du Cyclotron, Université de Liège, B-4000 Sart Tilman, Belgium.

出版信息

J Am Chem Soc. 2009 Oct 28;131(42):15262-9. doi: 10.1021/ja9051526.

DOI:10.1021/ja9051526
PMID:19919161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2896319/
Abstract

6-Beta-halogenopenicillanates are powerful, irreversible inhibitors of various beta-lactamases and penicillin-binding proteins. Upon acylation of these enzymes, the inhibitors are thought to undergo a structural rearrangement associated with the departure of the iodide and formation of a dihydrothiazine ring, but, to date, no structural evidence has proven this. 6-Beta-iodopenicillanic acid (BIP) is shown here to be an active antibiotic against various bacterial strains and an effective inhibitor of the class A beta-lactamase of Bacillus subtilis BS3 (BS3) and the D,D-peptidase of Actinomadura R39 (R39). Crystals of BS3 and of R39 were soaked with a solution of BIP and their structures solved at 1.65 and 2.2 A, respectively. The beta-lactam and the thiazolidine rings of BIP are indeed found to be fused into a dihydrothiazine ring that can adopt two stable conformations at these active sites. The rearranged BIP is observed in one conformation in the BS3 active site and in two monomers of the asymmetric unit of R39, and is observed in the other conformation in the other two monomers of the asymmetric unit of R39. The BS3 structure reveals a new mode of carboxylate interaction with a class A beta-lactamase active site that should be of interest in future inhibitor design.

摘要

6-β-卤代青霉烷酸盐是各种β-内酰胺酶和青霉素结合蛋白的强、不可逆抑制剂。这些酶被酰化后,抑制剂被认为会发生结构重排,伴随着碘化物的离去和二氢噻嗪环的形成,但迄今为止,还没有结构证据证明这一点。这里显示 6-β-碘代青霉烷酸(BIP)是一种对抗各种细菌株具有活性的抗生素,也是枯草芽孢杆菌 BS3(BS3)的 A 类β-内酰胺酶和 Actinomadura R39(R39)的 D,D-肽酶的有效抑制剂。BS3 和 R39 的晶体分别用 BIP 的溶液浸泡,并分别在 1.65 和 2.2 A 的分辨率下解决其结构。BIP 的β-内酰胺和噻唑烷环确实融合成一个二氢噻嗪环,在这些活性部位可以采用两种稳定的构象。在 BS3 的活性部位的一个构象中观察到重排的 BIP,在 R39 的不对称单元的两个单体中观察到另一个构象,在 R39 的不对称单元的另外两个单体中观察到另一个构象。BS3 的结构揭示了一种新的羧酸盐与 A 类β-内酰胺酶活性部位相互作用的模式,这在未来的抑制剂设计中应该是有趣的。

相似文献

1
Structural basis of the inhibition of class A beta-lactamases and penicillin-binding proteins by 6-beta-iodopenicillanate.6-β-碘代青霉烷酸抑制 A 类β-内酰胺酶和青霉素结合蛋白的结构基础。
J Am Chem Soc. 2009 Oct 28;131(42):15262-9. doi: 10.1021/ja9051526.
2
Interactions of "bora-penicilloates" with serine β-lactamases and DD-peptidases.“硼青霉素酯”与丝氨酸β-内酰胺酶和 DD-肽酶的相互作用。
Biochemistry. 2014 Oct 21;53(41):6530-8. doi: 10.1021/bi500970f. Epub 2014 Oct 10.
3
Primary and predicted secondary structures of the Actinomadura R39 extracellular DD-peptidase, a penicillin-binding protein (PBP) related to the Escherichia coli PBP4.马杜拉放线菌R39细胞外DD-肽酶的一级结构和预测的二级结构,一种与大肠杆菌PBP4相关的青霉素结合蛋白(PBP)
Biochem J. 1992 Mar 15;282 ( Pt 3)(Pt 3):781-8. doi: 10.1042/bj2820781.
4
Mechanisms of proton relay and product release by Class A β-lactamase at ultrahigh resolution.超高分辨率下 A 类β-内酰胺酶的质子传递和产物释放机制。
FEBS J. 2018 Jan;285(1):87-100. doi: 10.1111/febs.14315. Epub 2017 Nov 20.
5
Dual substrate specificity of Bacillus subtilis PBP4a.枯草芽孢杆菌 PBP4a 的双底物特异性。
Biochemistry. 2013 Apr 16;52(15):2627-37. doi: 10.1021/bi400211q. Epub 2013 Apr 5.
6
Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.耐抑制剂的A类β-内酰胺酶:在SHV-1变体的阿泊巴坦和他唑巴坦结构中观察到的Ser130突变为Gly的后果。
Biochemistry. 2004 Nov 9;43(44):14111-7. doi: 10.1021/bi0487903.
7
Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.对由Ser130Gly SHV(一种对临床抑制剂具有抗性的β-内酰胺酶)形成的中间体进行的拉曼晶体学研究。
Biochemistry. 2007 Jul 24;46(29):8689-99. doi: 10.1021/bi700581q. Epub 2007 Jun 27.
8
Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase.设计、合成及 6-亚烷基-2'-取代青霉素酸砜类化合物的晶体结构作为耐碳青霉烯类鲍曼不动杆菌 OXA-24 型碳青霉烯酶的强效抑制剂。
J Am Chem Soc. 2010 Sep 29;132(38):13320-31. doi: 10.1021/ja104092z.
9
Crystal structures of complexes of bacterial DD-peptidases with peptidoglycan-mimetic ligands: the substrate specificity puzzle.细菌DD-肽酶与肽聚糖模拟配体复合物的晶体结构:底物特异性之谜。
J Mol Biol. 2008 Aug 29;381(2):383-93. doi: 10.1016/j.jmb.2008.06.012. Epub 2008 Jun 10.
10
Interaction of beta-iodopenicillanate with the beta-lactamases of Streptomyces albus G and Actinomadura R39.β-碘青霉烷酸与白色链霉菌G和马杜拉放线菌R39的β-内酰胺酶的相互作用
Biochem J. 1982 Dec 1;207(3):437-44. doi: 10.1042/bj2070437.

引用本文的文献

1
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.青霉素衍生物通过与 SARS-CoV-2 主蛋白酶的亲核半胱氨酸反应来抑制该酶。
J Med Chem. 2022 Jun 9;65(11):7682-7696. doi: 10.1021/acs.jmedchem.1c02214. Epub 2022 May 12.
2
Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 DD-peptidase activities by ceftaroline.头孢洛林对肺炎链球菌青霉素结合蛋白 2x 和游动放线菌 R39DD-肽酶活性的抑制作用。
Antimicrob Agents Chemother. 2013 Jan;57(1):661-3. doi: 10.1128/AAC.01593-12. Epub 2012 Nov 12.
3
Development of new drugs for an old target: the penicillin binding proteins.

本文引用的文献

1
The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis.青霉素结合蛋白:结构及其在肽聚糖生物合成中的作用
FEMS Microbiol Rev. 2008 Mar;32(2):234-58. doi: 10.1111/j.1574-6976.2008.00105.x. Epub 2008 Feb 11.
2
Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity.头孢妥仑与肺炎链球菌青霉素结合蛋白2X复合物的晶体结构:其高抗菌活性的结构基础
Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7. doi: 10.1128/AAC.00743-07. Epub 2007 Aug 27.
3
Anti-MRSA beta-lactams in development.
开发针对老靶点的新药:青霉素结合蛋白。
Molecules. 2012 Oct 24;17(11):12478-505. doi: 10.3390/molecules171112478.
4
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.KPC-2 酶中 237 位残基对底物的选择性和抑制剂识别的新作用。
Antimicrob Agents Chemother. 2010 Jul;54(7):2867-77. doi: 10.1128/AAC.00197-10. Epub 2010 Apr 26.
5
Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.当前抗菌药物化疗的挑战:聚焦β-内酰胺酶抑制。
Drugs. 2010 Apr 16;70(6):651-79. doi: 10.2165/11318430-000000000-00000.
Curr Opin Pharmacol. 2006 Oct;6(5):480-5. doi: 10.1016/j.coph.2006.06.002. Epub 2006 Aug 8.
4
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion.基于经历TLS运动的多个基团对蛋白质结构进行的最优描述。
Acta Crystallogr D Biol Crystallogr. 2006 Apr;62(Pt 4):439-50. doi: 10.1107/S0907444906005270. Epub 2006 Mar 18.
5
Crystal structure of the Actinomadura R39 DD-peptidase reveals new domains in penicillin-binding proteins.马杜拉放线菌R39 DD-肽酶的晶体结构揭示了青霉素结合蛋白中的新结构域。
J Biol Chem. 2005 Sep 2;280(35):31249-56. doi: 10.1074/jbc.M503271200. Epub 2005 Jun 29.
6
Coot: model-building tools for molecular graphics.Coot:分子图形的模型构建工具。
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32. doi: 10.1107/S0907444904019158. Epub 2004 Nov 26.
7
Refinement of macromolecular structures by the maximum-likelihood method.用最大似然法优化大分子结构。
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55. doi: 10.1107/S0907444996012255.
8
The CCP4 suite: programs for protein crystallography.CCP4软件包:用于蛋白质晶体学的程序。
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3. doi: 10.1107/S0907444994003112.
9
Understanding the acylation mechanisms of active-site serine penicillin-recognizing proteins: a molecular dynamics simulation study.理解活性位点丝氨酸青霉素识别蛋白的酰化机制:分子动力学模拟研究
Proteins. 2003 Oct 1;53(1):88-100. doi: 10.1002/prot.10450.
10
Synthesis and biological evaluation of 6-bromo-6-substituted penicillanic acid derivatives as beta-lactamase inhibitors.
Farmaco. 2002 Aug;57(8):663-9. doi: 10.1016/s0014-827x(02)01261-2.